San Diego, CA, United States of America

Matthew Reissman

USPTO Granted Patents = 2 

Average Co-Inventor Count = 8.0

ph-index = 1

Forward Citations = 3(Granted Patents)


Company Filing History:


Years Active: 2022-2024

Loading Chart...
2 patents (USPTO):Explore Patents

Title: The Innovations of Matthew Reissman

Introduction

Matthew Reissman is a notable inventor based in San Diego, California. He has made significant contributions to the field of biotechnology, particularly in the development of humanized antibodies. With a total of two patents to his name, Reissman is recognized for his innovative approaches to treating inflammatory bowel diseases.

Latest Patents

Reissman's latest patents include the development of humanized antibodies to TNF-like ligand 1A (TL1A) and their uses. These patents describe humanized anti-TL1A antibodies and pharmaceutical compositions aimed at treating inflammatory bowel disease (IBD), including Crohn's Disease (CD) and ulcerative colitis (UC). His work in this area has the potential to significantly impact the treatment options available for patients suffering from these conditions.

Career Highlights

Throughout his career, Matthew Reissman has worked with prominent organizations such as Prometheus Biosciences, Inc. and Cedars-Sinai Medical Center. His experience in these institutions has allowed him to collaborate with leading experts in the field and contribute to groundbreaking research.

Collaborations

Some of Reissman's notable coworkers include Jeffry Dean Watkins and Cindy T. Dickerson. Their collaborative efforts have further advanced the research and development of innovative treatments in the biotechnology sector.

Conclusion

Matthew Reissman stands out as an influential inventor in the biotechnology field, particularly with his work on humanized antibodies for treating inflammatory bowel diseases. His contributions continue to pave the way for advancements in medical treatments.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…